Adaptive Biotechnologies Corp

NASDAQ: ADPT
$4.69
+$0.32 (+7.3%)
Closing Price on November 22, 2024

ADPT Stock Chart and Intraday Price

ADPT Stock Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Address 1551 EASTLAKE AVENUE EAST SUITE 200, SEATTLE, WA, US
Fiscal Year End December
Latest Quarter 12/31/2023
Market Cap 583.44M USD
Shares Outstanding 144,773,000
Adaptive Biotechnologies Corp is at the forefront of harnessing the power of the immune system to improve disease diagnosis and treatment. With a focus on immune medicine, the company's innovative platform offers deep insights into the adaptive immune system, aiding in the development of clinical immunomics data. Its notable product, the clonoSEQ diagnostic test, plays a crucial role in detecting and monitoring cancer cells post-treatment. Adaptive Biotechnologies also engages in significant partnerships, including with Genentech and Microsoft, to advance its mission of transforming disease detection and therapy.

ADPT Articles

These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with...
These five stocks that Cathie Wood's ARK funds own millions of shares of are perfect for aggressive investors who look to get share count leverage on companies that have sizable upside potential.
These five stocks that Cathie Wood's ARK funds own millions of shares of are perfect for aggressive investors who look to get share count leverage on companies that have sizable upside potential.
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with...
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with...
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with...
Friday afternoon's analyst upgrades and downgrades included Chubb, Domino’s, Lam Research, Moderna, Riot Blockchain and more.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Wednesday, including Microsoft, Oracle, Tesla, Virgin Galactic and more.